isoxazoles has been researched along with obeticholic acid in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 6 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bishop-Bailey, D; Li, YT; Swales, KE; Thomas, GJ; Warner, TD | 1 |
| Alawad, AS; Levy, C | 1 |
| Ali, MS; Bishop-Bailey, D; Bye, AP; Dombrowicz, D; Dorchies, E; Flora, GD; Gibbins, JM; Kriek, N; Molendi-Coste, O; Moraes, LA; Sage, T; Sasikumar, P; Staels, B; Unsworth, AJ; Vaiyapuri, S | 1 |
| Kainuma, M; Makishima, M; Sano, K; Takada, I | 1 |
| Kowdley, KV; Shah, RA | 1 |
| Badman, MK; Bao, D; Bursulaya, B; Chianelli, D; Chu, A; Groessl, T; Hernandez, ED; Hill, R; Huang, DJ; Joseph, SB; Kim, Y; Laffitte, B; Liu, B; Liu, X; Liu, Y; McNamara, P; Molteni, V; Nelson, J; Phimister, A; Prashad, M; Richmond, W; Roland, J; Rucker, PV; Sancho-Martinez, I; Schlama, T; Schmeits, J; Seidel, HM; Tully, DC; Wu, J; Zoll, J | 1 |
| Adorini, L; Anfuso, B; Rosso, N; Tiribelli, C | 1 |
| Camilleri, M; Vijayvargiya, P | 1 |
| Brunst, S; Ebert, R; Helmstädter, M; Kramer, JS; Merk, D; Proschak, E; Schierle, S; Steinhilber, D | 1 |
| Bertolini, A; Bloks, VW; Chen, S; de Wit, S; Havinga, R; Jašprová, J; Jonker, JW; Mennillo, E; Rettenmeier, E; Schreuder, AB; Struik, D; Tukey, RH; Valášková, P; van der Schoor, LWE; Verkade, HJ; Vítek, L; Weber, AA | 1 |
3 review(s) available for isoxazoles and obeticholic acid
| Article | Year |
|---|---|
FXR Agonists: From Bench to Bedside, a Guide for Clinicians.
Topics: Animals; Azepines; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholestasis; Drug Evaluation, Preclinical; Gastrointestinal Agents; Hepatitis, Autoimmune; Humans; Hypertension, Portal; Indoles; Isoxazoles; Liver Cirrhosis, Alcoholic; Liver Cirrhosis, Biliary; Liver Diseases; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid | 2016 |
Current and potential treatments for primary biliary cholangitis.
Topics: Benzothiazoles; Bezafibrate; Bile Acids and Salts; Budesonide; Case-Control Studies; Chenodeoxycholic Acid; Cholagogues and Choleretics; Clinical Trials as Topic; Cyclosporine; Disease Progression; Glucocorticoids; Homeostasis; Humans; Immunologic Factors; Immunosuppressive Agents; Isoxazoles; Liver Cirrhosis, Biliary; Liver Transplantation; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Rituximab; Treatment Outcome; United States; United States Food and Drug Administration; Ursodeoxycholic Acid | 2020 |
The Role of Bile Acids in Chronic Diarrhea.
Topics: Benzothiazoles; Bile Acids and Salts; Chenodeoxycholic Acid; Cholestenones; Cholestyramine Resin; Chronic Disease; Colesevelam Hydrochloride; Colestipol; Diarrhea; Diet, Fat-Restricted; Feces; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Isoxazoles; Liver; Malabsorption Syndromes; Receptors, Cytoplasmic and Nuclear; Sequestering Agents; Taurocholic Acid | 2020 |
7 other study(ies) available for isoxazoles and obeticholic acid
| Article | Year |
|---|---|
Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration.
Topics: Animals; Anti-Inflammatory Agents; Becaplermin; Cell Line; Cell Movement; Cell Survival; Cells, Cultured; Chenodeoxycholic Acid; Cyclooxygenase 2; DNA-Binding Proteins; Dose-Response Relationship, Drug; Genes, Reporter; Humans; Inflammation; Interleukin-1beta; Isoxazoles; Ligands; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NF-kappa B; Nitric Oxide Synthase Type II; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Rats; Receptors, Cytoplasmic and Nuclear; RNA Interference; RNA, Messenger; RNA, Small Interfering; Transcription Factors; Transcription, Genetic; Transfection | 2007 |
Farnesoid X Receptor and Its Ligands Inhibit the Function of Platelets.
Topics: Animals; Blood Platelets; Calcium Signaling; Chenodeoxycholic Acid; Cyclic GMP; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinogen; Genotype; Hemostasis; Humans; Isoxazoles; Ligands; Mice, Inbred C57BL; Mice, Knockout; Phenotype; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Cytoplasmic and Nuclear; Thrombosis; Time Factors | 2016 |
Farnesoid X Receptor Activation Enhances Transforming Growth Factor β-Induced Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Cells.
Topics: Bile Acids and Salts; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Chenodeoxycholic Acid; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Isoxazoles; Liver; Liver Neoplasms; Receptors, Cytoplasmic and Nuclear; Transforming Growth Factor beta1 | 2018 |
Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
Topics: Animals; Benzothiazoles; Chenodeoxycholic Acid; Diet, High-Fat; Dogs; Humans; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Protein Structure, Tertiary; Rats; Receptors, Cytoplasmic and Nuclear; Treatment Outcome | 2020 |
Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model.
Topics: Benzamides; Benzothiazoles; Bile Acids and Salts; Cell Line; Chenodeoxycholic Acid; Coculture Techniques; Collagen; Fatty Acids, Nonesterified; Hepatic Stellate Cells; Hepatocytes; Humans; Imidazoles; Isoxazoles; Liver; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Non-alcoholic Fatty Liver Disease; Protein Kinase Inhibitors; Pyridines; Receptors, Cytoplasmic and Nuclear; RNA-Binding Proteins | 2020 |
Development and in vitro Profiling of Dual FXR/LTA4H Modulators.
Topics: Chenodeoxycholic Acid; Drug Development; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Isoxazoles; Molecular Structure; Receptors, Cytoplasmic and Nuclear | 2021 |
Potential of therapeutic bile acids in the treatment of neonatal Hyperbilirubinemia.
Topics: Animals; Bile Acids and Salts; Bilirubin; Chenodeoxycholic Acid; Hyperbilirubinemia, Neonatal; Ileum; Isoxazoles; Liver; Mice; Rats, Gunn; Receptors, Cytoplasmic and Nuclear; Treatment Outcome; Ursodeoxycholic Acid | 2021 |